Literature DB >> 2458487

Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

P S Linsley1, J A Ledbetter, E Kinney-Thomas, S L Hu.   

Abstract

Monoclonal antibodies (MAbs) to defined peptide epitopes on gp120 from human immunodeficiency virus type 1 were used to investigate the involvement of their epitopes in gp120 binding to the CD4 receptor. Recombinant vaccinia viruses were constructed that expressed either full-length gp120 (v-ED6), or a truncated gp120 lacking 44 amino acids at the carboxyl terminus (v-ED4). Binding of these glycoproteins to the CD4 receptor was detected directly with metabolically labeled gp120 or indirectly with the gp120 MAbs. Truncated gp120 from v-ED4 bound to CD4-positive cells less than 1/12 as well as gp120 from v-ED6, indicating that the C-terminal region of gp120, which is conserved in numerous isolates of human immunodeficiency virus type 1, is critical for CD4 binding. However, MAb 110-1, which recognizes a peptide contained in the region deleted from v-ED4 (amino acids 489 through 511), did not inhibit binding of gp120 to CD4. MAb 110-1 also reacted with gp120 bound to the CD4 receptor, indicating that the epitope for this antibody does not directly interact with CD4. A second MAb, 110-4, which recognizes a peptide epitope located between amino acids 303 and 323 and has potent viral neutralizing activity, also bound to gp120 on the CD4 receptor. Furthermore, pretreatment of gp120 with MAb 110-4 at concentrations approximately 1,000-fold higher than those required for complete virus neutralization inhibited subsequent CD4 binding by only about 65%. Taken together, these data suggest that neutralization mediated by antibody 110-4 does not result from binding of this MAb to the CD4-binding site of gp120.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458487      PMCID: PMC253512     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  An immunoglobulin light chain dimer with CD4 antigen specificity.

Authors:  J A Ledbetter; H P Fell; L S Grosmaire; N A Norris; T T Tsu
Journal:  Mol Immunol       Date:  1987-12       Impact factor: 4.407

2.  Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.

Authors:  S L Hu; G D Plowman; P Sridhar; U S Stevenson; J P Brown; C D Estin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

Review 3.  Mechanisms of neutralization of animal viruses.

Authors:  N J Dimmock
Journal:  J Gen Virol       Date:  1984-06       Impact factor: 3.891

Review 4.  The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses.

Authors:  P W Choppin; A Scheid
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

5.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.

Authors:  R L Willey; D H Smith; L A Lasky; T S Theodore; P L Earl; B Moss; D J Capon; M A Martin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  66 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1.

Authors:  C Terai; R S Kornbluth; C D Pauza; D D Richman; D A Carson
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

7.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef.

Authors:  O Schwartz; Y Rivière; J M Heard; O Danos
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.